MANGOCEUTICALS INC (MGRX) Fundamental Analysis & Valuation

NASDAQ:MGRX • US56270V2051

Current stock price

0.4822 USD
-0.03 (-5.43%)
Last:

This MGRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MGRX Profitability Analysis

1.1 Basic Checks

  • In the past year MGRX has reported negative net income.
  • MGRX had a negative operating cash flow in the past year.
  • In the past 5 years MGRX always reported negative net income.
  • MGRX had a negative operating cash flow in each of the past 5 years.
MGRX Yearly Net Income VS EBIT VS OCF VS FCFMGRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 -5M -10M -15M -20M

1.2 Ratios

  • MGRX has a Return On Assets of -131.95%. This is amonst the worse of the industry: MGRX underperforms 94.59% of its industry peers.
  • With a Return On Equity value of -139.67%, MGRX is not doing good in the industry: 83.78% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -131.95%
ROE -139.67%
ROIC N/A
ROA(3y)-356.32%
ROA(5y)-269.29%
ROE(3y)-464.99%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MGRX Yearly ROA, ROE, ROICMGRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

1.3 Margins

  • MGRX has a better Gross Margin (54.92%) than 94.59% of its industry peers.
  • MGRX's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for MGRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.09%
GM growth 5YN/A
MGRX Yearly Profit, Operating, Gross MarginsMGRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025 0 -5K -10K -15K -20K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. MGRX Health Analysis

2.1 Basic Checks

  • MGRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MGRX has been increased compared to 1 year ago.
  • MGRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MGRX Yearly Shares OutstandingMGRX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 5M 10M 15M
MGRX Yearly Total Debt VS Total AssetsMGRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 5M 10M 15M

2.2 Solvency

  • MGRX has an Altman-Z score of -1.55. This is a bad value and indicates that MGRX is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -1.55, MGRX is not doing good in the industry: 89.19% of the companies in the same industry are doing better.
  • There is no outstanding debt for MGRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.55
ROIC/WACCN/A
WACC8.86%
MGRX Yearly LT Debt VS Equity VS FCFMGRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 5M -5M 10M 15M

2.3 Liquidity

  • A Current Ratio of 1.74 indicates that MGRX should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.74, MGRX is in the better half of the industry, outperforming 78.38% of the companies in the same industry.
  • MGRX has a Quick Ratio of 1.74. This is a normal value and indicates that MGRX is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.74, MGRX belongs to the top of the industry, outperforming 89.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 1.74
MGRX Yearly Current Assets VS Current LiabilitesMGRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 500K 1M 1.5M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. MGRX Growth Analysis

3.1 Past

  • MGRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.45%, which is quite impressive.
  • MGRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -25.96%.
  • Measured over the past years, MGRX shows a very strong growth in Revenue. The Revenue has been growing by 271.41% on average per year.
EPS 1Y (TTM)46.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.96%
Revenue 1Y (TTM)-25.96%
Revenue growth 3Y271.41%
Revenue growth 5YN/A
Sales Q2Q%-10.35%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MGRX Yearly Revenue VS EstimatesMGRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 200K 400K 600K

More info and screens

Find the best growth stocksShow best growing peers

0

4. MGRX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MGRX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MGRX Price Earnings VS Forward Price EarningsMGRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGRX Per share dataMGRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MGRX Dividend Analysis

5.1 Amount

  • MGRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MGRX Fundamentals: All Metrics, Ratios and Statistics

MANGOCEUTICALS INC

NASDAQ:MGRX (4/21/2026, 9:38:32 AM)

0.4822

-0.03 (-5.43%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)04-01
Earnings (Next)05-13
Inst Owners14.95%
Inst Owner Change0.04%
Ins Owners10.02%
Ins Owner Change-0.82%
Market Cap8.18M
Revenue(TTM)456.10K
Net Income(TTM)-21.23M
AnalystsN/A
Price TargetN/A
Short Float %6.65%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.94
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB 8.45
EV/EBITDA N/A
EPS(TTM)-2.5
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.03
BVpS0.9
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -131.95%
ROE -139.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.92%
FCFM N/A
ROA(3y)-356.32%
ROA(5y)-269.29%
ROE(3y)-464.99%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.09%
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.74
Quick Ratio 1.74
Altman-Z -1.55
F-Score3
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.96%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-25.96%
Revenue growth 3Y271.41%
Revenue growth 5YN/A
Sales Q2Q%-10.35%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-120.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.28%
OCF growth 3YN/A
OCF growth 5YN/A

MANGOCEUTICALS INC / MGRX Fundamental Analysis FAQ

What is the fundamental rating for MGRX stock?

ChartMill assigns a fundamental rating of 3 / 10 to MGRX.


What is the valuation status of MANGOCEUTICALS INC (MGRX) stock?

ChartMill assigns a valuation rating of 0 / 10 to MANGOCEUTICALS INC (MGRX). This can be considered as Overvalued.


How profitable is MANGOCEUTICALS INC (MGRX) stock?

MANGOCEUTICALS INC (MGRX) has a profitability rating of 1 / 10.


What is the financial health of MANGOCEUTICALS INC (MGRX) stock?

The financial health rating of MANGOCEUTICALS INC (MGRX) is 6 / 10.